Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

The Growth Of New COVID-19 Cases In Europe Dragged EUR, GBP

Published 10/14/2020, 06:16 AM
Updated 03/21/2024, 07:45 AM

Global markets are sagging on Wednesday as Johnson & Johnson (NYSE:JNJ) and Eli Lilly (NYSE:LLY) announced the suspension of their respective vaccine and antibody treatment trials. Investors seem even more disappointed with the delay in the fiscal stimulus package for the American economy.

US market gave back some recent gains on worries about relief package, vaccine trial
  
These reports have made us realise that developing a vaccine is not a straightforward and easy path, and very often, developers must act with extreme caution. However, one should not overestimate this news. The shares of these companies fell by 2.3% and 3.0%, respectively, which can hardly be called a big crash. 
  
Perhaps more disappointing than the markets is the impasse in negotiations on the relief package. House Speaker Nancy Pelosi rejected the White House's $1.8 trillion offer and there are expectations that the stimulus package will not be agreed before the presidential election. In our view, we should still expect Trump to take a big step just before the election to attract the electorate to his side.

EURUSD under pressure with COVID-19 cases growth
  
Many seem to be speculating on the market with the same idea, as after a very limited decline on Tuesday, futures for the US indices are mixed on Wednesday morning. 
  
However, the currency market is showing more signs of caution. The dollar added about 0.6% on Tuesday and is growing against the euro at the start of trading on Wednesday. EURUSD has retreated from levels above 1.1800 to 1.1735. GBPUSD dropped to 1.2880 against 1.3060 early on Tuesday. 
  
The infection rate dynamics may again become a driver on the stock and currency markets. In the first case, we see an inverse correlation between the number of infections and the demand for risk assets. In the case of currencies, changes in the incidence ratio in one country/region relative to another play an important role.  
  
The new records in the UK and France have set the issue of lockdown in these countries back on the agenda. Germany is once again in the top 15 countries in terms of daily case growth. Against this backdrop, the United States no longer looks so bad that it reinforces purchases of the dollar against the euro and the pound.

The FxPro Analyst Team

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.